Form 4: CRISPR Therapeutics Executive James R. Kasinger Reports Stock Transactions
SEC Form 4 Filing
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On March 20, 2025, James R. Kasinger vested 6,250 restricted stock units (RSUs) which convert into common shares of CRISPR Therapeutics.
- Following the vesting, Kasinger sold 3,185 common shares on March 21, 2025, at a price of $41.23 per share to cover tax withholding obligations.
- After these transactions, Kasinger directly owns 81,729 common shares.
- Kasinger also holds 18,750 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions related to vesting of restricted stock units and subsequent tax obligation fulfillment. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the trading activities of company insiders.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of grant for the restricted stock unit award with respect to 25,000 Common Shares. |
| 03/20/2025 | Vesting date for 6,250 restricted stock units. |
| 03/21/2025 | Date of sale of 3,185 common shares at $41.23 per share. |
| 03/20/2026 | Next vesting date for one quarter of the shares from the restricted stock unit award. |
| 03/20/2027 | Next vesting date for one quarter of the shares from the restricted stock unit award. |
| 03/20/2028 | Final vesting date for one quarter of the shares from the restricted stock unit award. |
| 03/24/2025 | Date of signature for the Form 4 filing. |
Keywords
CRISPR Therapeutics, CRSP, James R. Kasinger, Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, RSU, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.